The haemorrhagic transformation of cerebral infarction: classification; pathogenesis; predictors and effect on the functional outcome


如何引用文章

全文:

详细

Using specific keywords; we searched for articles from the last 10 years on haemorrhagic transformation (HT) of cerebral infarction (CI); which were available on the PubMed database. This article provides an analysis and a summary of the information on the classification; pathogenesis and predictors (clinical; laboratory; neuroimaging; including the use of integrative assessment scales) of HT; as well as its impact on the functional outcome of the condition. It is emphasized that HT is a multifactorial pathological process in its phenomenology; including brain ischaemia; the development of coagulopathy; disturbances in the integrity of the blood–brain barrier and reperfusion injury. The emphasis is placed on careful monitoring of patients with acute ischaemic infarct after intravenous thrombolytic therapy and/or endovascular intervention; as well as those patients with a high predicted risk of HT. Timely and regular neuroimaging should be carried out to detect HT as soon as possible. Type 2 parenchymal haematomas; the most severe type of HT; are most often associated with high mortality and an unfavourable functional outcome.

作者简介

Dina Khasanova

Kazan State Medical University; Interregional Clinical Diagnostic Centre

Email: ninilak@gmail.com
俄罗斯联邦, Kazan

Mikhail Kalinin

Kazan State Medical University; Interregional Clinical Diagnostic Centre

编辑信件的主要联系方式.
Email: ninilak@gmail.com
俄罗斯联邦, Kazan

Мurat Ibatullin

Kazan State Medical University; Interregional Clinical Diagnostic Centre

Email: ninilak@gmail.com
俄罗斯联邦, Kazan

Ilnur Rakhimov

Elabuga Institute (Branch) of the Kazan (Volga Region) Federal University

Email: ninilak@gmail.com
俄罗斯联邦, Elabuga

参考

  1. Berger C., Fiorelli M., Steiner T. et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001; 32: 1330–1335. doi: 10.1161/01.STR.32.6.1330. PMID: 11387495.
  2. Lei C., Wu B., Liu M. et al. Asymptomatic hemorrhagic transformation after acute ischemic stroke: is it clinically innocuous? J Stroke Cerebrovasc Dis 2014; 23: 2767–2772. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.024. PMID: 25314946.
  3. Sussman E.S., Connolly E.S.Jr. Hemorrhagic transformation: a review of the rate of hemorrhage in the major clinical trials of acute ischemic stroke. Front Neurol 2013; 4: 69. doi: 10.3389/fneur.2013.00069. PMID: 23772220.
  4. Lee Y.B., Yoon W., Lee Y.Y. et al. Predictors and impact of hemorrhagic transformations after endovascular thrombectomy in patients with acute large vessel occlusions. J Neurointerv Surg 2018; 11: 469–473. doi: 10.1136/neurintsurg-2018-014080. PMID: 30291207.
  5. Wolpert S.M., Bruckmann H., Greenlee R. et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. Am J Neuroradiol 1993; 14: 3-13. PMID: 8427107.
  6. Trouillas P., von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006; 37: 556–561. doi: 10.1161/01.STR.0000196942.84707.71. PMID: 16397182.
  7. von Kummer R., Broderick J.P., Campbell B.C. et al. The Heidelberg Bleeding Classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke 2015; 46: 2981–2986. doi: 10.1161/STROKEAHA.115.010049. PMID: 26330447.
  8. Hacke W., Kaste M., Bluhmki E. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359: 1317–1329. doi: 10.1056/NEJMoa0804656. PMID: 18815396.
  9. Gumbinger C., Gruschka P., Böttinger M. et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke 2012; 43: 240–242. doi: 10.1161/STROKEAHA.111.623033. PMID: 21998049.
  10. Seet R.C., Rabinstein A.A. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis 2012; 34: 106–114. doi: 10.1159/000339675. PMID: 22868870.
  11. Rao N.M., Levine S.R., Gornbein J.A. et al. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Stroke 2014; 45: 2728–2733. doi: 10.1161/STROKEAHA.114.005135. PMID: 25096731.
  12. Yaghi S., Willey J.Z., Cucchiara B. et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2017; 48: e343–e361. doi: 10.1161/STR.0000000000000152. PMID: 29097489.
  13. Jickling G.C., Liu D., Stamova B. et al. Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab 2014; 34: 185–199. doi: 10.1038/jcbfm.2013.203. PMID: 24281743.
  14. Jaillard A., Cornu C., Durieux A. et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke 1999; 30: 1326–1332. doi: 10.1161/01.STR.30.7.1326. PMID: 10390303.
  15. Bang O.Y., Saver J.L., Kim S.J. et al. Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke. Stroke 2011; 42: 2235-2239. doi: 10.1161/STROKEAHA.110.604603. PMID: 21737798.
  16. Terruso V., D'Amelio M., Di Benedetto N. et al. Frequency and determinants for hemorrhagic transformation of cerebral infarction. Neuroepidemiology 2009; 33: 261–265. doi: 10.1159/000229781. PMID: 19641332.
  17. Paciaroni M., Agnelli G., Corea F. et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008; 39: 2249–2256. doi: 10.1161/STROKEAHA.107.510321. PMID: 18535273.
  18. Larrue V., von Kummer R.R., Muller A. et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II) Stroke 2001; 32: 438–441. doi: 10.1161/01.STR.32.2.438. PMID: 11157179.
  19. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587. doi: 10.1056/NEJM199512143332401. PMID: 7477192.
  20. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28: 2109–2118. doi: 10.1161/01.STR.28.11.2109. PMID: 9368550.
  21. Clark W.M., Wissman S., Albers G.W. et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999; 282: 2019–2026. doi: 10.1001/jama.282.21.2019. PMID: 10591384.
  22. Hao Y., Zhang Z., Zhang H. et al. Risk of intracranial hemorrhage after endovascular treatment for acute ischemic stroke: systematic review and meta-analysis. Interv Neurol 2017; 6: 57–64. doi: 10.1159/000454721. PMID: 28611835.
  23. Thomalla G., Sobesky J., Kohrmann M. et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 2007; 38: 313–318. doi: 10.1161/01.STR.0000254565.51807.22. PMID: 17204683.
  24. Hamann G.F., del Zoppo G.J., von Kummer R. Hemorrhagic transformation of cerebral infarction--possible mechanisms. Thromb Haemost 1999; 82 Suppl 1: 92–94. PMID: 10695495.
  25. Vandelli L., Marietta M., Gambini M. et al. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2015; 24: 394–400. doi: 10.1016/j.jstrokecerebrovasdis.2014.09.005. PMID: 25497721.
  26. Matosevic B., Knoflach M., Werner P. et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology 2013; 80: 1216–1224. doi: 10.1212/WNL.0b013e3182897015. PMID: 23486872.
  27. Lee V.H., Conners J.J., Cutting S. et al. Elevated international normalized ratio as a manifestation of post-thrombolytic coagulopathy in acute ischemic stroke. J Stroke Cerebrovasc Dis 2014; 23: 2139–2144. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.021. PMID: 25081309.
  28. Wang X., Lee S.R., Arai K.иet al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9: 1313–1317. doi: 10.1038/nm926. PMID: 12960961.
  29. Kelly M.A., Shuaib A., Todd K.G. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol 2006; 200: 38–49. doi: 10.1016/j.expneurol.2006.01.032. PMID: 16624294.
  30. Suzuki Y., Nagai N., Umemura K. Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator. J Pharmacol Sci 2011; 116: 25–29. doi: 10.1254/jphs.10R27FM. PMID: 21498957.
  31. Wang X., Tsuji K., Lee S.R. et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004; 35: 2726–2730. doi: 10.1161/01.STR.0000143219.16695.af. PMID: 15459442.
  32. Hamann G.F., Liebetrau M., Martens H. et al. Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 2002; 22: 526–533. doi: 10.1097/00004647-200205000-00004. PMID: 11973425.
  33. Rossi D.J., Brady J.D., Mohr C. Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci 2007; 10: 1377–1386. doi: 10.1038/nn2004. PMID: 17965658.
  34. Warach S., Latour L.L. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004; 35: 2659–2661. doi: 10.1161/01.STR.0000144051.32131.09. PMID: 15472105.
  35. Latour L.L., Kang D.W., Ezzeddine M.A. et al. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004; 56: 468–477. doi: 10.1002/ana.20199. PMID: 15389899.
  36. Klohs J., Steinbrink J., Bourayou R. et al. Near-infrared fluorescence imaging with fluorescently labeled albumin: a novel method for non-invasive optical imaging of blood-brain barrier impairment after focal cerebral ischemia in mice. J Neurosci Methods 2009; 180: 126–132. doi: 10.1016/j.jneumeth.2009.03.002. PMID: 19427539.
  37. Sandoval K.E., Witt K.A. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008; 32: 200–219. doi: 10.1016/j.nbd.2008.08.005. PMID: 18790057.
  38. Khatri R., McKinney A.M., Swenson B. et al. Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology 2012; 79: S52–S57. doi: 10.1212/WNL.0b013e3182697e70. PMID: 23008413.
  39. Kidwell C.S., Saver J.L., Carneado J. et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002; 33: 717–724. doi: 10.1161/hs0302.104110. PMID: 11872894.
  40. Whiteley W.N., Slot K.B., Fernandes P. et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012; 43: 2904–2909. doi: 10.1161/STROKEAHA.112.665331. PMID: 22996959.
  41. Lyden P.D. Hemorrhagic transformation during thrombolytic therapy and reperfusion: effects of age, blood pressure, and matrix metalloproteinases. J Stroke Cerebrovasc Dis 2013; 22: 532–538. doi: 10.1016/j.jstrokecerebrovasdis.2013.02.001. PMID: 23453556.
  42. Elgebaly M.M., Ogbi S., Li W. et al. Neurovascular injury in acute hyperglycemia and diabetes: A comparative analysis in experimental stroke. Transl Stroke Res 2011; 2: 391–398. doi: 10.1007/s12975-011-0083-3. PMID: 21909340.
  43. Xing Y., Jiang X., Yang Y. et al. Hemorrhagic transformation induced by acute hyperglycemia in a rat model of transient focal ischemia. Acta Neurochir Suppl 2011; 111: 49–54. doi: 10.1007/978-3-7091-0693-8_9. PMID: 21725731.
  44. Dankbaar J.W., Hom J., Schneider T. et al. Age- and anatomy-related values of blood-brain barrier permeability measured by perfusion-CT in non-stroke patients. J Neuroradiol 2009; 36: 219–227. doi: 10.1016/j.neurad.2009.01.001. PMID: 19251320.
  45. Tejima E., Katayama Y., Suzuki Y. et al. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke 2001; 32: 1336–1340. doi: 10.1161/01.STR.32.6.1336. PMID: 11387496.
  46. Butcher K., Christensen S., Parsons M. et al. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke 2010; 41: 72–77. doi: 10.1161/STROKEAHA.109.563767. PMID: 19926841.
  47. Ahmed N., Wahlgren N., Brainin M. et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009; 40: 2442–2449. doi: 10.1161/STROKEAHA.109.548602. PMID: 19461022.
  48. Jauch E.C., Saver J.L., Adams H.P.Jr. et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870–947. doi: 10.1161/STR.0b013e318284056a. PMID: 23370205.
  49. Tuttle J.L., Sanders B.M., Burkhart H.M. et al. Impaired collateral artery development in spontaneously hypertensive rats. Microcirculation 2002; 9: 343–351. doi: 10.1038/sj.mn.7800151. PMID: 12375172.
  50. Pires P.W., Dams Ramos C.M., Matin N. et al. The effects of hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol 2013; 304: H1598–H1614. doi: 10.1152/ajpheart.00490.2012. PMID: 23585139.
  51. de Courten-Myers G.M., Kleinholz M., Holm P. et al. Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med 1992; 21: 120–126. doi: 10.1016/S0196-0644(05)80144-1. PMID: 1739195.
  52. Kawai N., Keep R.F., Betz A.L. Hyperglycemia and the vascular effects of cerebral ischemia. Stroke 1997; 28: 149–154. doi: 10.1161/01.STR.28.1.149. PMID: 8996504.
  53. Bruno A., Durkalski V.L., Hall C.E. et al. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. Int J Stroke 2014; 9: 246–251. doi: 10.1111/ijs.12045. PMID: 23506245.
  54. Tu H.T., Campbell B.C., Christensen S. et al. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation. Int J Stroke 2015; 10: 534–540. doi: 10.1111/ijs.12007. PMID: 23489996.
  55. Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467–1507. doi: 10.1093/europace/euv309. PMID: 26324838.
  56. Seiffge D.J., Werring D.J., Paciaroni M., et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol 2019; 18: 117–126. doi: 10.1016/S1474-4422(18)30356-9. PMID: 30415934.
  57. Hankey G.J. Dual antiplatelet therapy in acute transient ischemic attack and minor stroke. N Engl J Med 2013; 369: 82–83. doi: 10.1056/NEJMe1305127. PMID: 23803138.
  58. Cucchiara B., Tanne D., Levine S.R. et al. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis 2008; 17: 331–333. doi: 10.1016/j.jstrokecerebrovasdis.2008.03.012. PMID: 18984422.
  59. Nardi K., Leys D., Eusebi P. et al. Influence of lipid profiles on the risk of hemorrhagic transformation after ischemic stroke: systematic review. Cerebrovasc Dis Extra 2011; 1: 130–141. doi: 10.1159/000335014. PMID: 22566990.
  60. Bang O.Y., Saver J.L., Liebeskind D.S. et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007; 68: 737–742. doi: 10.1212/01.wnl.0000252799.64165.d5. PMID: 17182976.
  61. D’Amelio M., Terruso V., Famoso G. et al. Cholesterol levels and risk of hemorrhagic transformation after acute ischemic stroke. Cerebrovasc Dis 2011; 32: 234–238. doi: 10.1159/000329315. PMID: 21860236.
  62. Kim B.J., Lee S.H., Ryu W.S. et al. Low level of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism. Stroke 2009; 40: 1627–1632. doi: 10.1161/STROKEAHA.108.539643. PMID: 19286585.
  63. Scheitz J.F., MacIsaac R.L., Abdul-Rahim A.H. et al. Statins and risk of poststroke hemorrhagic complications. Neurology 2016; 86: 1590–1596. doi: 10.1212/WNL.0000000000002606. PMID: 27016519.
  64. Engelter S.T., Soinne L., Ringleb P. et al. IV thrombolysis and statins. Neurology 2011; 77: 888–895. doi: 10.1212/WNL.0b013e31822c9135. PMID: 21849650.
  65. Campos M., García-Bonilla L., Hernández-Guillamon M. et al. Combining statins with tissue plasminogen activator treatment after experimental and human stroke: a safety study on hemorrhagic transformation. CNS Neurosci Ther 2013; 19: 863–870. doi: 10.1111/cns.12181. PMID: 24118905.
  66. Thrift A., McNeil J., Donnan G. et al. Reduced frequency of high cholesterol levels among patients with intracerebral haemorrhage. J Clin Neurosci 2002; 9: 376–380. doi: 10.1054/jocn.2002.1111. PMID: 12217665.
  67. Xing Y., Guo Z.N., Yan S. et al. Increased globulin and its association with hemorrhagic transformation in patients receiving intra-arterial thrombolysis therapy. Neurosci Bull 2014; 30: 469–476. doi: 10.1007/s12264-013-1440-x. PMID: 24871645.
  68. Rodríguez-Yáñez M., Castellanos M., Blanco M. et al. Micro- and macroalbuminuria predict hemorrhagic transformation in acute ischemic stroke. Neurology 2006; 67: 1172–1177. doi: 10.1212/01.wnl.0000238353.89194.08. PMID: 17030748.
  69. Cho B.H., Kim J.T., Chang J. et al. Prediction of hemorrhagic transformation in acute ischaemic stroke by micro- and macroalbuminuria after intravenous thrombolysis. Eur J Neurol 2013; 20: 1145–1152. doi: 10.1111/ene.12127. PMID: 23582041.
  70. Foerch C., Wunderlich M.T., Dvorak F. et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007; 38: 2491–2495. doi: 10.1161/STROKEAHA.106.480111. PMID: 17673718.
  71. Castellanos M., Leira R., Serena J. et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671–1676. doi: 10.1161/01.STR.0000131656.47979.39. PMID: 15166391.
  72. Lee J.G., Lee K.B., Jang I.M. et al. Low glomerular filtration rate increases hemorrhagic transformation in acute ischemic stroke. Cerebrovasc Dis 2013; 35: 53–59. doi: 10.1159/000345087. PMID: 23428997.
  73. Choi K.H., Park M.S., Kim J.T. et al. The serum ferritin level is an important predictor of hemorrhagic transformation in acute ischaemic stroke. Eur J Neurol 2012; 19: 570–577. doi: 10.1111/j.1468-1331.2011.03564.x. PMID: 21999175.
  74. Nikiforova (Postnikova) T.A., Doronin B.M., Peskov S.A. [Blood serum cytokines as predictors of hemorrhagic transformation of ischemic stroke]. Zh Nevrol Psikhiatr im S.S. Korsakova 2014; 114 (3 Pt 2): 20–26. PMID: 24781237. (In Russ.)
  75. Inzitari D., Giusti B., Nencini P. et al. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death. Stroke 2013; 44: 2901–2903. doi: 10.1161/STROKEAHA.113.002274. PMID: 23908067.
  76. Christoforidis G.A., Karakasis C., Mohammad Y. et al. Predictors of hemorrhage following intra-arterial thrombolysis for acute ischemic stroke: the role of pial collateral formation. Am J Neuroradiol 2009; 30: 165–170. doi: 10.3174/ajnr.A1276. PMID: 18768718.
  77. Mendioroz M., Fernández-Cadenas I., Alvarez-Sabín J. et al. Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients. Cerebrovasc Dis 2009; 28: 143–50. doi: 10.1159/000225907. PMID: 19546541.
  78. Zhang J., Yang Y., Sun H. et al. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med 2014; 2: 81. doi: 10.3978/j.issn.2305-5839.2014.08.08. PMID: 25333056.
  79. Hoffmann A., Zhu G., Wintermark M. Advanced neuroimaging in stroke patients: prediction of tissue fate and hemorrhagic transformation. Expert Rev Cardiovasc Ther 2012; 10: 515–524. doi: 10.1586/erc.12.30. PMID: 22458583.
  80. Rowley H. The four Ps of acute stroke imaging: parenchyma, pipes, perfusion, and penumbra. Am J Neuroradiol 2001; 22: 599–601. PMID: 11290464.
  81. Castellanos M., Leira R., Serena J. et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34: 40–46. doi: 10.1161/01.STR.0000046764.57344.31. PMID: 12511748.
  82. Tan S., Wang D., Liu M. et al. Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol 2014; 261: 905–912. doi: 10.1007/s00415-014-7297-8. PMID: 24590407.
  83. IMS Study Investigators. Hemorrhage in the Interventional Management of Stroke study. Stroke 2006; 37: 847–851. doi: 10.1161/01.STR.0000202586.69525.ae. PMID: 16439694.
  84. Larrue V., von Kummer R., del Zoppo G. et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997; 28: 957–960. PMID: 9158632.
  85. Lin K., Zink W.E., Tsiouris A.J. et al. Risk assessment of hemorrhagic transformation of acute middle cerebral artery stroke using multimodal CT. J Neuroimaging 2012; 22: 160–166. doi: 10.1111/j.1552-6569.2010.00562.x. PMID: 21143549.
  86. Molina C.A., Montaner J., Abilleira S. et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001; 32: 1079–1084. doi: 10.1161/01.STR.32.5.1079. PMID: 11340213.
  87. Toni D., Fiorelli M., Bastianello S. et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996; 46: 341–345. doi: 10.1212/WNL.46.2.341. PMID: 8614491.
  88. Barber P.A., Demchuk A.M., Zhang J. et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000; 355: 1670–1674. doi: 10.1016/S0140-6736(00)02237-6. PMID: 10905241.
  89. Lin K., Lee S.A., Zink W.E. What ASPECTS value best predicts the 100-mL threshold on diffusion weighted imaging? Study of 150 patients with middle cerebral artery stroke. J Neuroimaging 2011; 21: 229–231. doi: 10.1111/j.1552-6569.2010.00487.x. PMID: 20609038.
  90. Puetz V., Sylaja P.N., Hill M.D. et al. CT angiography source images predict final infarct extent in patients with basilar artery occlusion. Am J Neuroradiol 2009; 30: 1877–1883. doi: 10.3174/ajnr.A1723. PMID: 19643923.
  91. Schwamm L.H., Rosenthal E.S., Swap C.J. et al. Hypoattenuation on CT angiographic source images predicts risk of intracerebral hemorrhage and outcome after intra-arterial reperfusion therapy. Am J Neuroradiol 2005; 26: 1798–1803. PMID: 16091532.
  92. Campbell B.C., Christensen S., Butcher K.S. et al. Regional very low cerebral blood volume predicts hemorrhagic transformation better than diffusion-weighted imaging volume and thresholded apparent diffusion coefficient in acute ischemic stroke. Stroke 2010; 41: 82–88. doi: 10.1161/STROKEAHA.109.562116. PMID: 19959537.
  93. Campbell B.C., Costello C., Christensen S. et al. Fluid-attenuated inversion recovery hyperintensity in acute ischemic stroke may not predict hemorrhagic transformation. Cerebrovasc Dis 2011; 32: 401–405. doi: 10.1159/000331467. PMID: 21986096.
  94. Cho A.H., Kim J.S., Kim S.J. et al. Focal fluid-attenuated inversion recovery hyperintensity within acute diffusion-weighted imaging lesions is associated with symptomatic intracerebral hemorrhage after thrombolysis. Stroke 2008; 39: 3424–3426. doi: 10.1161/STROKEAHA.108.516740. PMID: 18772449.
  95. Kufner A., Galinovic I., Brunecker P. et al. Early infarct FLAIR hyperintensity is associated with increased hemorrhagic transformation after thrombolysis. Eur J Neurol 2013; 20: 281–285. doi: 10.1111/j.1468-1331.2012.03841.x. PMID: 22900825.
  96. Oppenheim C., Samson Y., Dormont D. et al. DWI prediction of symptomatic hemorrhagic transformation in acute MCA infarct. J Neuroradiol 2002; 29: 6–13. PMID: 11984472.
  97. Sakamoto Y., Kimura K., Iguchi Y.et al. Hemorrhagic transformation in acute cerebellar infarction. Cerebrovasc Dis 2011; 32: 327–333. doi: 10.1159/000329259. PMID: 21921595.
  98. Selim M., Fink J.N., Kumar S. et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002; 33: 2047–2052. doi: 10.1161/01.STR.0000023577.65990.4E. PMID: 12154261.
  99. Singer O.C., Humpich M.C., Fiehler J. et al. Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann Neurol 2008; 63: 52–60. doi: 10.1002/ana.21222. PMID: 17880020.
  100. Tong D.C., Adami A., Moseley M.E. et al. Relationship between apparent diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke. Stroke 2000; 31: 2378–2384. doi: 10.1161/01.STR.31.10.2378. PMID: 11022067.
  101. Huang P., Chen C.H., Lin W.C. et al. Clinical applications of susceptibility weighted imaging in patients with major stroke. J Neurol 2012; 259: 1426–1432. doi: 10.1007/s00415-011-6369-2. PMID: 22186853.
  102. Kakuda W., Thijs V.N., Lansberg M.G. et al. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 2005; 65: 1175–1178. doi: 10.1212/01.wnl.0000180519.27680.0f. PMID: 16247042.
  103. Kidwell C.S., Saver J.L., Villablanca J.P. et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke 2002; 33: 95–98. doi: 10.1161/hs0102.101792. PMID: 11779895.
  104. Lee S.H., Kang B.S., Kim N. et al. Does microbleed predict haemorrhagic transformation after acute atherothrombotic or cardioembolic stroke? J Neurol Neurosurg Psychiatry 2008; 79: 913–916. doi: 10.1136/jnnp.2007.133876. PMID: 18187478.
  105. Celik Y., Utku U., Asil T. et al. Factors affecting haemorrhagic transformation in middle cerebral artery infarctions. J Clin Neurosci 2004; 11: 656–658. doi: 10.1016/j.jocn.2003.08.001. PMID: 15261244.
  106. Shi Z.S., Loh Y., Liebeskind D.S. et al. Leukoaraiosis predicts parenchymal hematoma after mechanical thrombectomy in acute ischemic stroke. Stroke 2012; 43: 1806–1811. doi: 10.1161/STROKEAHA.111.649152. PMID: 22581819.
  107. Costello C.A., Campbell B.C., Perez de la Ossa N. et al. Age over 80 years is not associated with increased hemorrhagic transformation after stroke thrombolysis. J Clin Neurosci 2012; 19: 360–363. doi: 10.1016/j.jocn.2011.08.014. PMID: 22245278.
  108. Kimura K., Sakai K., Iguchi Y. et al. Does ICA occlusion frequently have intracerebral hemorrhage after IV tissue plasminogen activator therapy for ischemic stroke? Eur Neurol 2011; 65: 245–249. doi: 10.1159/000326338. PMID: 21464569.
  109. Puetz V., Dzialowski I., Hill MD. et al. Intracranial thrombus extent predicts clinical outcome, final infarct size and hemorrhagic transformation in ischemic stroke: the clot burden score. Int J Stroke 2008; 3: 230–236. doi: 10.1111/j.1747-4949.2008.00221.x. PMID: 18811738.
  110. Tan I.Y., Demchuk A.M., Hopyan J. et al. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. Am J Neuroradiol 2009; 30: 525–531. doi: 10.3174/ajnr.A1408. PMID: 19147716.
  111. Flacke S., Urbach H., Keller E. et al. Middle cerebral artery (MCA) susceptibility sign at susceptibility-based perfusion MR imaging: clinical importance and comparison with hyperdense MCA sign at CT. Radiology 2000; 215: 476–482. doi: 10.1148/radiology.215.2.r00ma09476. PMID: 10796928.
  112. Haring H.P., Dilitz E., Pallua A. et al. Attenuated corticomedullary contrast: An early cerebral computed tomography sign indicating malignant middle cerebral artery infarction. A case-control study. Stroke 1999; 30: 1076–1082. doi: 10.1161/01.STR.30.5.1076. PMID: 10229747.
  113. Kharitonova T., Ahmed N., Thorén M. et al. Hyperdense middle cerebral artery sign on admission CT scan--prognostic significance for ischaemic stroke patients treated with intravenous thrombolysis in the safe implementation of thrombolysis in Stroke International Stroke Thrombolysis Register. Cerebrovasc Dis 2009; 27: 51–59. doi: 10.1159/000172634. PMID: 19018138.
  114. Manno E.M., Nichols D.A., Fulgham J.R. et al. Computed tomographic determinants of neurologic deterioration in patients with large middle cerebral artery infarctions. Mayo Clin Proc 2003; 78: 156–160. doi: 10.4065/78.2.156. PMID: 12583526.
  115. Paliwal P.R., Ahmad A., Shen L. et al. Persistence of hyperdense middle cerebral artery sign on follow-up CT scan after intravenous thrombolysis is associated with poor outcome. Cerebrovasc Dis 2012; 33: 446–452. doi: 10.1159/000336863. PMID: 22456065.
  116. Zou M., Churilov L., He A. et al. Hyperdense middle cerebral artery sign is associated with increased risk of hemorrhagic transformation after intravenous thrombolysis for patients with acute ischaemic stroke. J Clin Neurosci 2013; 20: 984–987. doi: 10.1016/j.jocn.2012.10.013. PMID: 23664409.
  117. Abul-Kasim K., Selariu E., Brizzi M. et al. Hyperdense middle cerebral artery sign in multidetector computed tomography: definition, occurrence, and reliability analysis. Neurol India 2009; 57: 143–150. doi: 10.4103/0028-3886.51282. PMID: 19439843.
  118. Koo C.K., Teasdale E., Muir K.W. What constitutes a true hyperdense middle cerebral artery sign? Cerebrovasc Dis 2000; 10: 419–423. doi: 10.1159/000016101. PMID: 11070370.
  119. Shobha N., Bal S., Boyko M. et al. Measurement of length of hyperdense MCA sign in acute ischemic stroke predicts disappearance after IV tPA. J Neuroimaging 2014; 24: 7–10. doi: 10.1111/j.1552-6569.2012.00761.x. PMID: 23316960.
  120. Guo G., Yang Y., Yang W. Validation of hyperintense middle cerebral artery sign in acute ischemic stroke: Comparison between magnetic resonance imaging and angiography. Neural Regen Res 2012; 7: 229–234. doi: 10.3969/j.issn.1673-5374.2012.03.013. PMID: 25767505.
  121. Zheng M., Fan D.S. Acute cardioembolic and thrombotic middle cerebral artery occlusions have different morphological susceptibility signs on T2 (∗) -weighted magnetic resonance images. Biomed Res Int 2015; 2015: 839820. doi: 10.1155/2015/839820. PMID: 26543869.
  122. Hermier M., Nighoghossian N., Derex L. et al. Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator. J Cereb Blood Flow Metab 2003; 23: 1362–1370. doi: 10.1097/01.WCB.0000091764.61714.79. PMID: 14600444.
  123. Hohenhaus M., Schmidt W.U., Brunecker P. et al. FLAIR vascular hyperintensities in acute ICA and MCA infarction: a marker for mismatch and stroke severity? Cerebrovasc Dis 2012; 34: 63–69. doi: 10.1159/000339012. PMID: 22759720.
  124. Arenillas J.F., Rovira A., Molina C.A. et al. Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke. Stroke 2002; 33: 2197–2203. doi: 10.1161/01.STR.0000027861.75884.DF. PMID: 12215587.
  125. García-Bermejo P., Calleja A.I., Pérez-Fernández S. et al. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study. Cerebrovasc Dis 2012; 34: 31–37. doi: 10.1159/000338778. PMID: 22759450.
  126. Kassner A., Mandell D.M., Mikulis D.J. Measuring permeability in acute ischemic stroke. Neuroimaging Clin N Am 2011; 21: 315–325. doi: 10.1016/j.nic.2011.01.004. PMID: 21640302.
  127. Viallon M., Altrichter S., Pereira V.M. et al. Combined use of pulsed arterial spin-labeling and susceptibility-weighted imaging in stroke at 3T. Eur Neurol 2010; 64: 286–296. doi: 10.1159/000321162. PMID: 20980761.
  128. Hjort N., Wu O., Ashkanian M. et al. MRI detection of early blood-brain barrier disruption: parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis. Stroke 2008; 39: 1025–1028. doi: 10.1161/STROKEAHA.107.497719. PMID: 18258832.
  129. Kassner A., Liu F., Thornhill R.E. et al. Prediction of hemorrhagic transformation in acute ischemic stroke using texture analysis of postcontrast T1-weighted MR images. J Magn Reson Imaging 2009; 30: 933–941. doi: 10.1002/jmri.21940. PMID: 19856407.
  130. Kim E.Y., Na D.G., Kim S.S. et al. Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. Am J Neuroradiol 2005; 26: 1050–1055. PMID: 15891158.
  131. Vo K.D., Santiago F., Lin W., et al. MR imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. Am J Neuroradiol 2003; 24: 674–679. PMID: 12695202.
  132. Hom J., Dankbaar J.W., Soares B.P. et al. Blood-brain barrier permeability assessed by perfusion CT predicts symptomatic hemorrhagic transformation and malignant edema in acute ischemic stroke. Am J Neuroradiol 2011; 32: 41–48. doi: 10.3174/ajnr.A2244. PMID: 20947643.
  133. Kassner A., Roberts T.P., Moran B. et al. Recombinant tissue plasminogen activator increases blood-brain barrier disruption in acute ischemic stroke: an MR imaging permeability study. Am J Neuroradiol 2009; 30: 1864–1869. doi: 10.3174/ajnr.A1774. PMID: 19661169.
  134. Kassner A., Roberts T., Taylor K. et al. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. Am J Neuroradiol 2005; 26: 2213–2217. PMID: 16219824.
  135. Vidarsson L., Thornhill R.E., Liu F., et al. Quantitative permeability magnetic resonance imaging in acute ischemic stroke: how long do we need to scan? J Magn Reson Imaging 2009; 27: 1216–1222. doi: 10.1016/j.mri.2009.01.019. PMID: 19695816.
  136. Whiteley W.N., Thompson D., Murray G. et al. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial. Stroke 2014; 45: 1000–1006. doi: 10.1161/STROKEAHA.113.004362. PMID: 24603072.
  137. Gore J.M., Sloan M., Price T.R., et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study: Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 1991; 83: 448–459. PMID: 1899364.
  138. Hacke W., Kaste M., Fieschi C. et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245–1251. doi: 10.1016/S0140-6736(98)08020-9. PMID: 9788453.
  139. Wahlgren N., Ahmed N., Dávalos A. et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275–282. doi: 10.1016/S0140-6736(07)60149-4. PMID: 17258667.
  140. Strbian D., Sairanen T., Meretoja A. et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology 2011; 77: 341–348. doi: 10.1212/WNL.0b013e3182267b8c. PMID: 21715707.
  141. del Zoppo G.J., von Kummer R., Hamann G.F. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998; 65: 1–9. doi: 10.1136/jnnp.65.1.1. PMID: 9667553.
  142. Arnould M.C., Grandin C.B., Peeters A. et al. Comparison of CT and three MR sequences for detecting and categorizing early (48 hours) hemorrhagic transformation in hyperacute ischemic stroke. Am J Neuroradiol 2004; 25: 939–944. PMID: 15205127.
  143. Barber P.A., Darby D.G., Desmond P.M. et al. Identification of major ischemic change. Diffusion-weighted imaging versus computed tomography. Stroke 1999; 30: 2059–2065. PMID: 10512907.
  144. Goos J.D., van der Flier W.M., Knol D.L. et al. Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. Stroke 2011; 42: 1894–1900. doi: 10.1161/STROKEAHA.110.599837. PMID: 21566235.
  145. Harada M., Morita N., Uno M. et al. Incidence and clinical correlation of intracranial hemorrhages observed by 3-tesla gradient echo T(2)*-weighted images following intravenous thrombolysis with recombinant tissue plasminogen activator. Cerebrovasc Dis 2010; 29: 571–575. doi: 10.1159/000306644. PMID: 20375500.
  146. Lin Y.H., Lou M., Zhu R.Y. et al. [Multi-mode MRI-based intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) reduces hemorrhagic transformation in ischemic stroke patients]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2012; 41: 665–671. PMID: 23239659. (In Chinese)
  147. Lindley R.I., Wardlaw J.M., Sandercock P.A. et al. Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis 2004; 13: 235–246. doi: 10.1016/j.jstrokecerebrovasdis.2004.03.003. PMID: 17903981.
  148. Renou P., Sibon I., Tourdias T. et al. Reliability of the ECASS radiological classification of postthrombolysis brain haemorrhage: a comparison of CT and three MRI sequences. Cerebrovasc Dis 2010; 29: 597–604. doi: 10.1159/000312867. PMID: 20413970.
  149. Lees K.R., Bluhmki E., von Kummer R. et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695–1703. doi: 10.1016/S0140-6736(10)60491-6. PMID: 20472172.
  150. Fiorelli M., Bastianello S., von Kummer R. et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999; 30: 2280–2284. doi: 10.1161/01.STR.30.11.2280. PMID: 10548658.
  151. Fiehler J., Remmele C., Kucinski T. et al. Reperfusion after severe local perfusion deficit precedes hemorrhagic transformation: an MRI study in acute stroke patients. Cerebrovasc Dis 2005; 19: 117–124. doi: 10.1159/000083180. PMID: 15640606.
  152. Thevathasan A., Naylor J., Churilov L. et al. Association between hemorrhagic transformation after endovascular therapy and poststroke seizures. Epilepsia 2018; 59: 403–409. doi: 10.1111/epi.13982. PMID: 29288487.
  153. Dzialowski I., Pexman J.H., Barber P.A. et al. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke 2007; 38: 75–79. doi: 10.1161/01.STR.0000251644.76546.62. PMID: 17122437.
  154. Park J.H., Ko Y., Kim W.J. et al. Is asymptomatic hemorrhagic transformation really innocuous. Neurology 2012; 78: 421–426. doi: 10.1212/WNL.0b013e318245d22c. PMID: 22282643.
  155. Motto C., Ciccone A., Aritzu E., et al. Hemorrhage after an acute ischemic stroke. MAST-I Collaborative Group. Stroke 1999; 30: 761–764. PMID: 10187875.
  156. Menon B.K., Saver J.L., Prabhakaran S. et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue–type plasminogen activator. Stroke 2012; 43: 2293–2299. doi: 10.1161/STROKEAHA.112.660415. PMID: 22811458.
  157. Pisters R., Lane D.A., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093–1100. doi: 10.1378/chest.10-0134. PMID: 20299623.
  158. Lou M., Safdar A., Mehdiratta M. et al. The HAT score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology 2008; 71: 1417–1423. doi: 10.1212/01.wnl.0000330297.58334.dd. PMID: 18955684.
  159. Marsh E.B., Llinas R.H., Hillis A.E. et al. Hemorrhagic transformation in patients with acute ischaemic stroke and an indication for anticoagulation. Eur J Neurol 2013; 20: 962–967. doi: 10.1111/ene.12126. PMID: 23521544.
  160. Kalinin M.N., Khasanova D.R., Ibatullin M.M. The hemorrhagic transformation index score: a prediction tool in middle cerebral artery ischemic stroke. BMC Neurol 2017; 17: 177. doi: 10.1186/s12883-017-0958-3. PMID: 28882130.
  161. Saposnik G., Fang J., Kapral M.K. et al. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke 2012; 43: 1315–1322. doi: 10.1161/STROKEAHA.111.646265. PMID: 22308252.
  162. Strbian D., Engelter S., Michel P. et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol 2012; 71: 634–641. doi: 10.1002/ana.23546. PMID: 22522478.
  163. Mazya M., Egido J.A., Ford G.A. et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012; 43: 1524–1531. doi: 10.1161/STROKEAHA.111.644815. PMID: 22442178.
  164. Flint A.C., Faigeles B.S., Cullen S.P. et al. THRIVE score predicts ischemic stroke outcomes and thrombolytic hemorrhage risk in VISTA. Stroke 2013; 44: 3365–3369. doi: 10.1161/STROKEAHA.113.002794. PMID: 24072004.
  165. Saposnik G., Guzik A.K., Reeves M. et al. Stroke prognostication using age and NIH Stroke Scale: SPAN-100. Neurology 2013; 80: 21–28. doi: 10.1212/WNL.0b013e31827b1ace. PMID: 23175723.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Khasanova D.R., Kalinin M.N., Ibatullin М.M., Rakhimov I.S., 2019

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».